Serdar Farhan, MD
Interventional Cardiology · New York, NYNPI 1417495508
Payments from drug & device makers
Across 544 payments — averaging $56.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$9K
- Abbott$4K
- Shockwave Medical, Inc$4K
- Boston Scientific$2K
- Edwards Lifesciences$986
- Ancora Heart, Inc.$943
- plus $9K from 29 others
What the payments were for
- Travel & lodging$10,03632%
- Food & beverage$20,62567%
- Education$3271%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 55 | $9,475 |
| Abbott | 83 | $4,285 |
| Shockwave Medical, Inc | 73 | $4,255 |
| Boston Scientific | 25 | $2,048 |
| Edwards Lifesciences | 12 | $986 |
| Ancora Heart, Inc. | 5 | $943 |
| Amgen | 29 | $832 |
| Cardiovascular Systems Inc. | 18 | $809 |
| Biotronik Inc. | 18 | $794 |
| Terumo Medical Corporation | 20 | $618 |
| Johnson & Johnson | 22 | $568 |
| AstraZeneca | 20 | $564 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 26 | $546 |
| E.r. Squibb & Sons, L.L.C. | 26 | $473 |
| Chiesi USA, Inc. | 21 | $452 |
| Philips North America LLC | 14 | $423 |
| Bard Peripheral Vascular, Inc. | 13 | $405 |
| Endologix LLC | 3 | $397 |
| Abiomed | 12 | $365 |
| Stryker | 3 | $350 |
| Pfizer | 12 | $301 |
| Cagent Vascular Inc | 6 | $198 |
| Cook Medical LLC | 6 | $133 |
| Veryan Medical Incorporated | 1 | $131 |
| W. L. Gore & Associates, Inc. | 3 | $100 |
| Penumbra, Inc. | 4 | $93 |
| Cardiva Medical, Inc. | 2 | $88 |
| Cordis US CORP. | 3 | $88 |
| Advanced Oxygen Therapy Inc. | 1 | $68 |
| Asahi Intecc USA, Inc. | 2 | $50 |
| Acist Medical Systems, Inc. | 1 | $43 |
| Inari Medical, Inc. | 2 | $31 |
| Heartflow, Inc. | 1 | $28 |
| Teleflex LLC | 1 | $28 |
| Merck | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$1,763
- OMNILINK ELITE$1,020
- VersaCross Access Solution$1,019
- AccuCinch$862
- Vascular Lithotripsy$704
- COREVALVE EVOLUT R$421
- ESPRIT$360
- PK Papyrus$347
- Torus Stent Graft System$314
- ENDOCROSS Device$314
- PRO-Kinetic Energy$235
- Pulsar$235
- Orsiro$235
- Astron; Pulsar; AstronPulsar$235
- FLOWTRIEVER CATHETER, S$182
- CT THROMBECTOMY SYSTEM KIT$182
- EMBOSHIELD NAV6$181
- Supera peripheral stent system$177
- SUPERA$173
- Perclose ProGlide suture mediated closure system$173
How this compares
$30,987 in reported general payments places this provider in the 65th percentile of 382 interventional cardiology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 83 | $91,142 |
| EliquisApixaban | 45 | $42,117 |
| EntrestoSacubitril/Valsartan | 33 | $29,246 |
| FarxigaDapagliflozin Propanediol | 46 | $28,150 |
| BrilintaTicagrelor | 19 | $14,665 |
| XareltoRivaroxaban | 11 | $9,691 |
| Praluent PenAlirocumab | 14 | $6,752 |
| Repatha SureclickEvolocumab | 12 | $6,315 |
| Ezetimibe | 67 | $1,806 |
| Atorvastatin Calcium | 173 | $1,479 |
| Metoprolol Succinate | 91 | $1,444 |
| Ranolazine ErRanolazine | 11 | $1,006 |
| Rosuvastatin Calcium | 95 | $922 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 32 | $916 |
| Valsartan | 24 | $805 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Brilinta | $564 | $42,81565 claims |
| PfizerEliquis | $301 | $42,11745 claims |
| Johnson & JohnsonXarelto | $568 | $9,69111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 382 interventional cardiology providers in New York.
Other interventional cardiology in New York
- Martin LeonNew York$13.5M
- Susheel KodaliNew York$6M
- Deepak BhattNew York$4.1M
- Samin SharmaNew York$3.7M
- Annapoorna KiniNew York$3.5M
- Sahil ParikhNew York$2.7M
- George DangasNew York$2.6M
- Prakash KrishnanNew York$2M
- Ajay KirtaneNew York$1.8M
- Shing-Chiu WongNew York$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.